RB, Walmart and Doctor on Demand partner on promotion
Walmart, Reckitt Benckiser and telehealth service Doctor on Demand have teamed up on an effort aimed at making healthcare more accessible. This fall, Walmart shoppers who buy such RB brands as Mucinex, Delsym, Airborne or Digestive Advantage online or in-store will receive a limited-time offer for a no-cost Doctor on Demand consultation.
“This initiative is a big first step in delivering on RB and Walmart’s shared purpose of unlocking every American’s right to healthier lives,” said Gregory Chabidon, chief medical officer USA of RB’s health unit. “We found through research that many Walmart shoppers are looking for new ways to take health matters into their own hands. However, despite consumers’ desire to take more control of their health, the path isn’t always clear, and access to fast, reliable and affordable healthcare solutions remains a cause of stress.”
Chabidon said the effort, which is part of RB’s larger commitment to provide more affordable healthcare access to consumers, was timed specifically at the start of cold and flu season.
“At Walmart, we are committed to the health and wellbeing of our consumers,” said Annie Walker, vice president of OTC merchandising at Walmart. “We believe that this collaboration will be a tremendous step forward in improving access to healthcare, during a time when people face challenges to getting the right treatment at the right time.”
Doctor on Demand CEO Hill Ferguson said the effort marks a step forward for telemedicine and awareness of the 24/7 service. “At Doctor On Demand, our physicians can treat 90% of the most common medical issues seen in the ER and urgent care, including cold and flu, skin and eye issues, allergies, back pain and more,” Ferguson said. “We’re proud to be driving innovative solutions that put patients first and improve access to care this cold and flu season and beyond.”
One Brands intros white chocolate truffle bar
One Brands is adding a little extra sweetness to its portfolio.
The Boulder, Colo.-based brand unveiled its new white chocolate truffle bar, which contains 20 g of protein and just one gram of sugar, the company said.
Featuring white chocolate with a dark chocolate drizzle and dark chocolate chips, the bar also is gluten-free.
“We observed significant growth in the white chocolate segment over the past few years and knew that this flavor profile would be a natural addition to our current roster of guilt-free indulgent bars,” Peter Burns, CEO of One Brands said. “We are thrilled to introduce White Chocolate Truffle as the first flavor of its kind in the bar category, and look forward to offering consumers another way to fuel their active lifestyles with our signature, unmatched taste and texture.”
One’s white chocolate truffle bar is available for purchase on the company’s website for the suggested retail price of $2.49 to $2.70, and will be expanding to further locations in the future.
Companion Medical, Ultimed win DSN/ECRM Buyers’ Choice Awards
Companion Medical won the Drug Store News/ECRM Buyers Choice award for its InPen Bluetooth-enabled pen for insulin delivery during ECRM’s recent Diabetes/Clinical Programs, Chronic Care Management & Adherence Solutions held in Oak Brook, Ill. Ultimed was a finalist for its UltiGuard Safe Pack that enables safe disposal of injection devices.
The two companies were selected from dozens of entries in the award program, samples of which were displayed in the ECRM hospitality area during the EPPS meetings. Buyers cast their votes based on product innovation and packaging.
“The winners of this year’s Buyers Choice awards are clear examples of the product innovation that buyers are seeking to promote adherence and safety around diabetes injections,” said Michael Castillo, senior vice president of pharmacy at ECRM. “Products like these help pharmacy retailers tremendously in their efforts to drive successful patient outcomes.”
San Diego-based Companion Medical develops technology to improve diabetes care. Its InPen product is the first and only FDA-cleared smart pen for insulin delivery, and was developed to address many of the issues both healthcare professionals and those living with diabetes face on a daily basis. Miscalculating doses of insulin, missing insulin doses, insulin stacking and lack of insulin data represent major challenges with managing diabetes on multiple daily injections.
The InPen system consists of a Bluetooth-enabled pen that is connected to an app that helps patients make more informed decisions about how to dose their rapid-acting insulin. Along with automatically capturing insulin doses from the pen, the app includes a dose calculator to help calculate the bolus doses, tracks insulin-on-board to help minimize insulin stacking, offers dose reminders to minimize missed doses, allows BG meter data integration — including CGM — and contains sharable reports for healthcare providers so they can make treatment adjustments. InPen is currently available for sale in the United States, accepts prefilled cartridges of either NovoLog or Humalog insulin, and is covered on most prescription plans.
Finalist UltiMed in Minneapolis is a manufacturer of medical injection devices that are complemented by a proprietary packaging system that enables safe disposal. Founded in 1988 as an importer of hypodermic needles and syringes, today the company owns and operates a manufacturing facility in De Smet, S.D., and coordinates production activities through key vendors in South Korea and other Asian countries.
The company’s patented and proprietary UltiGuard Safe Pack is the only FDA-approved dual-purpose system that combines needles and an approved sharps container for a single co-pay, and is a solution to expand on medication disposal programs to include sharps stewardship. The Safe Pack is compliant with sharps disposal guidelines in all 50 states. The dual-purpose system is marketed under the UltiCare brand and is available in a pen needle and insulin syringe format with 100 premium quality needles designed to optimize injection comfort.